Insulin Degludec/Insulin Aspart Administered Once Daily at Any Meal, With Insulin Aspart at Other Meals Versus a Standard Basal-Bolus Regimen in Patients With Type 1 Diabetes: A 26-week, phase 3, randomized, open-label, treat-to-target trial

OBJECTIVE: To evaluate efficacy and tolerability of a co-formulation of insulin degludec and insulin aspart (IDegAsp) with insulin aspart (IAsp) at other meals compared with basal-bolus therapy using insulin detemir (IDet) and IAsp. RESEARCH DESIGN AND METHODS: Adults (n = 548) with type 1 diabetes...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirsch, Irl B., Bode, Bruce, Courreges, Jean-Pierre, Dykiel, Patrik, Franek, Edward, Hermansen, Kjeld, King, Allen, Mersebach, Henriette, Davies, Melanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2012
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3476910/
https://www.ncbi.nlm.nih.gov/pubmed/22933438
http://dx.doi.org/10.2337/dc11-2503

Ejemplares similares

Ejemplares similares